Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness... see more

NDAQ:INM - Post Discussion

View:
Post by Bullknit101 on Oct 01, 2020 4:11pm

Organigram

InMed is ahead of Hyasynth in cannabiboid manufacturing and yet, the SP is struggling. Either Bruce Collwill has been ineffective with the NASDAQ Listing Or InMed is getting jerked around by the SEC because it's Canadian company. The US (executive power) has never been this hostile towards it's friends and allies so I wouldn't be surprised if some stupid regulations have been imposed to stimy foreign companies. Just venting - probably not true...like WTF is going on??? https://www.cantechletter.com/2020/10/organigrams-biosynthesis-bet-is-paying-off-says-raymond-james/
Comment by Linc1581 on Oct 01, 2020 9:33pm
I've exited about 95% of my position and taken a hefty loss with inmed. They haven't been able to get granted patents for the last 4 years and seems to be hitting more delays than expected on all fronts. The most concerning is they can't seem to drum up interest from investors based on volume action, but likely a result of no granted patents, low cash, reverse split, vague answers at ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities